Modern Health vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

Bristol Myers Squibb leads in AI visibility (80 vs 41)
Modern Health logo

Modern Health

EmergingHealthcare

Mental Health Benefits

Modern Health is an enterprise mental health platform providing personalized therapy, coaching, and wellbeing resources to employees through employer-sponsored benefits programs. HQ: San Francisco.

AI VisibilityBeta
Overall Score
C41
Category Rank
#350 of 596
AI Consensus
75%
Trend
stable
Per Platform
ChatGPT
46
Perplexity
41
Gemini
37

About

Modern Health is an enterprise mental health platform that provides employees access to licensed therapists, mental health coaches, and digital wellness resources through their employer-sponsored benefits. Founded in 2017 by Alyssa Jaffee and Erica Johnson, Modern Health delivers a clinically validated mental health benefit that employers offer to their workforce as part of comprehensive health benefits packages — giving employees same-week access to therapy and coaching rather than waiting months for a mental health appointment through traditional insurance.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

41
Overall Score
80
#350
Category Rank
#18
75
AI Consensus
83
stable
Trend
stable
46
ChatGPT
78
41
Perplexity
78
37
Gemini
80
46
Claude
84
39
Grok
77

Key Details

Category
Mental Health Benefits
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Modern Health
Mental Health Benefits

Integrations

Only Bristol Myers Squibb
Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.